By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

A resurgence of interest One reason that ADCs struggled to gain traction is due to their potential for toxicity. Mylotarg (gemtuzumab ozogamicin) is an ADC created by Pfizer and approved in 2000 ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun offering stock, wading into a market routed by Trump’s tariffs in pursuit of up ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in insightful discussions and building meaningful connections with industry ...

“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert ...